Why the study?
Does BHT-3009 induce antigen-specific immune tolerance and reduce inflammatory lesions on brain MRI in patients with multiple sclerosis?
Does BHT-3009 induce antigen-specific immune tolerance and reduce inflammatory lesions on brain MRI in patients with multiple sclerosis?
In patients with multiple sclerosis, BHT-3009 is safe and induces antigen-specific immune tolerance with a reduction in inflammatory brain MRI lesions.
This is the authors' abstract. We don't add key points for this paper.
In patients with MS, BHT-3009 is safe and induces antigen-specific immune tolerance with concordant reduction of inflammatory lesions on brain MRI.
Supports antigen-specific immunotherapy development in MS; extends preclinical tolerance concepts to randomized human proof-of-concept.
No takes yet. Share an insight, caveat, or question.
Bar‐Or et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: